<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link="#0563C1" vlink="#954F72"><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See below for a link to a new treatment for PCa.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Note that PCCN W-W receives some funding from Janssen Pharmaceutical.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Silverberg, Stacey [JOICA] [mailto:ssilver8@ITS.JNJ.com] <br><b>Sent:</b> July 4, 2018 5:57 PM<br><b>To:</b> Silverberg, Stacey [JOICA]<br><b>Subject:</b> Health Canada approves ERLEADA!<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US>Dear Gentlemen,<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>It is my pleasure to let you know that Health Canada approved Erleada© - the first treatment for men with non-metastatic castration resistant prostate cancer today. Please see attached the link to the announcement. <o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>As you will see, Dr. Stuart Edmonds from PCC is quoted in the article.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><a href="https://www.newswire.ca/news-releases/health-canada-approves-erleada-apalutamide-tablets-the-first-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer-687341551.html">https://www.newswire.ca/news-releases/health-canada-approves-erleada-apalutamide-tablets-the-first-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer-687341551.html</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>We are very excited to have a new oral treatment option for this patient population. Please feel free to cascade through your respective networks.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>As always, please do be in touch should you have questions.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>Kindest Regards,<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US>Stacey Silverberg<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>Stakeholder Engagement Manager<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif"'><img border=0 width=302 height=72 id="Picture_x0020_1" src="cid:image001.png@01D413C0.5C4DD400" alt="cid:image001.png@01D05536.B117DB30"><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>Business: (905) 763-1506<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>Mobile: (416) 948-3565<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>19 Greenbelt Drive, North York, Ontario, M3C 1L9 <o:p></o:p></span></p><p class=MsoNormal><span lang=FR-CA>E-mail : <a href="mailto:ssilver8@its.jnj.com"><span style='color:blue'>ssilver8@its.jnj.com</span></a><o:p></o:p></span></p><p class=MsoNormal><span lang=FR-CA><o:p> </o:p></span></p></div></body></html>